Finalist
Janssen MDT Roadshow
Summary of work
Following a stagnant period for therapy development, recent years have seen a multitude of new agents emerging for the treatment of mCRPC and there is a desire among clinicians to use precision medicine to improve treatment outcomes; however, there is a lack of knowledge on which agents to use when and for which patients, and many treatment decisions are made based on resource and convenience. Furthermore, with increased life expectancy, quality of life (QoL) has emerged as a key outcome for patients. Research revealed clinicians wanted to better understand how to select the best individualised treatment for each patient, and how they wanted to receive this education. The MDT Roadshows were designed to address this need for both education and support to change clinical practice, and were delivered in a forum that optimised learning and maximised the clinicians’ time.
In total, 14 meetings, including 267 healthcare professionals involved in the management of mCRPC were held across the UK. Long-term meeting evaluation showed that 80% of delegates actually made changes to their clinical practice as a result of attending the workshops, with 45–55% of respondents specifically citing increased frequency or detail of QoL discussions as a result of the meetings.
Judges’ comments
Here we saw how clear insights guided the strategy and robust assessment showed short and long-term outcomes. The expert faculty were hand-picked on the basis of knowledge, experience, and patient-centricity, making the meeting very patient-focused and the high satisfaction scores from attendees demonstrated the impact the programme had with those involved.
